Novel approaches to support therapeutic development in ultra-rare cancers
Food and Drug Administration
The purpose of this program is to support new approaches that can be applied to facilitate therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers. Specific areas of interest include, but are not limited to, the following examples: • Development of infrastructure for a coordination network and data repository for patient-level data across institutions and internationally to support drug development and regulatory decision-making for one or more ultra-rare cancers. • Investigations to explore opportunities to develop and validate early clinical endpoints and other novel efficacy endpoints for evaluation of treatments for ultra-rare cancers. • Development and implementation of a collaborative multi-stakeholder effort to support generation and use of real-world data leveraging a registry framework for use in development of new therapies for pediatric patients with diffuse midline glioma (DMG) (including diffuse intrinsic pontine glioma, DIPG). • Innovative approaches to identify new biologically-driven opportunities for clinical development of previously approved drugs or biologics (hereafter referred to as drugs)
Deadline
Not published. Check the funder's page.
Who can apply
Open to: Native American tribal organizations (other than Federally recognized tribal governments); State governments; Special district governments; Independent school districts; Public housing authorities/Indian housing authorities; Public and State controlled institutions of higher education; Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.
Sources
Grants.gov. Last updated 2026-10-26.
Always confirm eligibility and deadlines on the funder's own page before applying.